title: Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study.
abstract: OBJECTIVE
  The expression of vascular endothelial growth factor (VEGF) is elevated in diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants. We investigated the safety and efficacy of ranibizumab in DME involving the foveal center.
  
  
  METHODS
  This was a 12-month, multicenter, sham-controlled, double-masked study with eyes (age>18 years, type 1 or 2 diabetes, central retinal thickness [CRT]≥300 μm, and best corrected visual acuity [BCVA] of 73-39 ETDRS letters [Early Treatment Diabetic Retinopathy Study]) randomly assigned to intravitreal ranibizumab (0.3 or 0.5 mg; n=51 each) or sham (n=49). The treatment schedule comprised three monthly injections, after which treatment could be stopped/reinitiated with an opportunity for rescue laser photocoagulation (protocol-defined criteria). After month 1, dose-doubling was permitted (protocol-defined criteria, injection volume increased from 0.05 to 0.1 ml and remained at 0.1 ml thereafter). Efficacy (BCVA and CRT) and safety were compared between pooled ranibizumab and sham arms using the full analysis set (n=151, patients receiving≥1 injection).
  
  
  RESULTS
  At month 12, mean±SD BCVA improved from baseline by 10.3±9.1 letters with ranibizumab and declined by 1.4±14.2 letters with sham (P<0.0001). Mean CRT reduction was 194.2±135.1 μm with ranibizumab and 48.4±153.4 μm with sham (P<0.0001). Gain of ≥10 letters BCVA from baseline occurred in 60.8% of ranibizumab and 18.4% of sham eyes (P<0.0001). Safety data were consistent with previous studies of intravitreal ranibizumab.
  
  
  CONCLUSIONS
  Ranibizumab is effective in improving BCVA and is well tolerated in DME. Future clinical trials are required to confirm its long-term efficacy and safety.
authors.affiliation: Assistance Publique des Hôpitaux de Paris, Ophthalmology Department, Hôpital Lariboisièe, Paris, France.
authors.forename: Pascale
authors.initials: P
authors.lastname: Massin
authors.forename: Francesco
authors.initials: F
authors.lastname: Bandello
authors.forename: Justus G
authors.initials: JG
authors.lastname: Garweg
authors.forename: Lutz L
authors.initials: LL
authors.lastname: Hansen
authors.forename: Simon P
authors.initials: SP
authors.lastname: Harding
authors.forename: Michael
authors.initials: M
authors.lastname: Larsen
authors.forename: Paul
authors.initials: P
authors.lastname: Mitchell
authors.forename: Dianne
authors.initials: D
authors.lastname: Sharp
authors.forename: U E K
authors.initials: UE
authors.lastname: Wolf-Schnurrbusch
authors.forename: Margarita
authors.initials: M
authors.lastname: Gekkieva
authors.forename: Andreas
authors.initials: A
authors.lastname: Weichselberger
authors.forename: Sebastian
authors.initials: S
authors.lastname: Wolf
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab